Skip to Main content Skip to Navigation
New interface
Journal articles

Pathophysiological pathways in patients with heart failure and atrial fibrillation

Bernadet T Santema 1 Vicente Artola Arita 1 Iziah E Sama 1 Mariëlle Kloosterman 1 Maarten P van den Berg 1 Hans L A Nienhuis 1 Isabelle C van Gelder 1 Peter van Der Meer 1 Faiez Zannad 2, 3, 4, 5 Marco Metra 6 Jozine M ter Maaten 1 John G Cleland 7, 8, 9 Leong L Ng 10, 11 Stefan D Anker 12, 13, 14 Chim Lang 15, 16 Nilesh J Samani 10, 11 Kenneth Dickstein 17, 18 Gerasimos Filippatos 19, 20 Dirk J van Veldhuisen 1 Carolyn S P Lam 1, 21 Michiel Rienstra 1 Adriaan A Voors 1 
Abstract : Abstract Aims Atrial fibrillation (AF) and heart failure (HF) are two growing epidemics that frequently co-exist. We aimed to gain insights into underlying pathophysiological pathways in HF patients with AF by comparing circulating biomarkers using pathway overrepresentation analyses. Methods and Results From a panel of 92 biomarkers from different pathophysiological domains available in 1,620 patients with HF, we first tested which biomarkers were dysregulated in patients with HF and AF (n = 648) compared with patients in sinus rhythm (n = 972). Secondly, pathway overrepresentation analyses were performed to identify biological pathways linked to higher plasma concentrations of biomarkers in patients who had HF and AF. Findings were validated in an independent HF cohort (n = 1,219, 38% with AF). Patient with AF and HF were older, less often women, and less often had a history of coronary artery disease compared with those in sinus rhythm. In the index cohort, 24 biomarkers were upregulated in patients with AF and HF. In the validation cohort, 8 biomarkers were upregulated, which all overlapped with the 24 biomarkers found in the index cohort. The strongest up-regulated biomarkers in patients with AF were spondin-1 (fold change 1.18, p = 1.33x10−12), insulin-like growth factor-binding protein-1 (fold change 1.32, p = 1.08x10−8), and insulin-like growth factor-binding protein-7 (fold change 1.33, p = 1.35x10−18). Pathway overrepresentation analyses revealed that the presence of AF was associated with activation amyloid-beta metabolic processes, amyloid-beta formation, and amyloid precursor protein catabolic processes with a remarkable consistency observed in the validation cohort. Conclusion In two independent cohorts of patients with HF, the presence of AF was associated with activation of three pathways related to amyloid-beta. These hypothesis-generating results warrant confirmation in future studies. Translational Perspective Using an unbiased approach, we identified and validated dysregulation of three amyloid-beta related pathways in patients who had heart failure (HF) with concomitant atrial fibrillation (AF). Amyloid-beta depositions are a hallmark of Alzheimer’s disease, but might also play a role in pathophysiological processes outside the central nervous system. Biopsy studies are needed to confirm the pathophysiological role of amyloid-beta in patients with AF and HF. Diagnostic and therapeutic implications should be investigated in the light of potential pathophysiological overlap between the three aging-related epidemics: Alzheimer’s disease, AF and HF.
Complete list of metadata
Contributor : Erwan BOZEC Connect in order to contact the contributor
Submitted on : Tuesday, November 2, 2021 - 4:27:02 PM
Last modification on : Friday, November 25, 2022 - 6:32:08 PM
Long-term archiving on: : Thursday, February 3, 2022 - 7:32:48 PM


Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License




Bernadet T Santema, Vicente Artola Arita, Iziah E Sama, Mariëlle Kloosterman, Maarten P van den Berg, et al.. Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2021, pp.cvab331. ⟨10.1093/cvr/cvab331⟩. ⟨hal-03411938⟩



Record views


Files downloads